PPARG and Parkinsonism: Pioglitazone, an agonist of PPARγ, has been shown to halt progression of Parkinsonism in a rodent model, ostensibly by inhibiting microglial inflammation and proliferation,49 although it is difficult to conclude if this is a direct effect on microglia given that the compound can affect a number of cells in these models.